Commercial Driving After STEMI, PCI, and Cardiac Arrest: Return to Work Assessment

Critical Disqualifying Factors

The American College of Cardiology recommends that commercial drivers must be asymptomatic with no history of life-threatening arrhythmias or cardiac arrest to be medically cleared 1
An ejection fraction of 28% falls well below the recommended threshold of >40% for commercial drivers, significantly increasing the risk of sudden cardiac death, heart failure exacerbation, and arrhythmias during commercial driving 1
Resting LVEF is a critical safety parameter for high-hazard occupations, and this patient's LVEF of 28% poses a significant risk 3, 4

The American College of Cardiology states that commercial drivers in high-hazard occupations face stricter medical standards than non-commercial drivers because sudden incapacitation could result in catastrophic consequences for the public 3
Each state's Department of Motor Vehicles has specific criteria that must be met, which vary but universally require medical stability and low risk of sudden incapacitation 3

The American Heart Association recommends that non-commercial drivers can typically resume driving 1 week after uncomplicated MI or PCI if symptom-free and compliant with state laws 3, 5, 1
For complicated MI, driving should be delayed 2-3 weeks after symptom resolution, and this patient's cardiac arrest and severely reduced EF place him in the "complicated" category at minimum 3

The American College of Cardiology suggests that return to work rates after MI range from 63-94% for standard employment, with timing dependent on job physical demands 3, 5, 4
Graded exercise testing should measure MET levels achieved and compare to job requirements to assess functional capacity in high-risk patients 3, 5, 4, 1

The American Heart Association strongly recommends cardiac rehabilitation, which should be completed before considering any return to work, particularly for high-risk patients 5, 6, 7, 1
Aggressive secondary prevention is mandatory, including statin therapy to reduce LDL to <100 mg/dL with ≥30% reduction, and tobacco cessation is non-negotiable 5
Dual antiplatelet therapy must be maintained as prescribed, and blood pressure and diabetes control must be optimized 1, 2

The American College of Cardiology suggests that this patient likely meets criteria for implantable cardioverter-defibrillator (ICD) therapy for secondary prevention of sudden cardiac death 3